CPL207-280, a Potent and Safe GPR40 Agonist for the treatment of Type 2 Diabetes

被引：2
|
作者：
Bazydlo-Guzenda, Katarzyna
Buda, Pawel
Kozlowska, Izabela
Mach, Mateusz
Teska-Kaminska, Malgorzata
Stelmach, Filip
Wasinska-Kalwa, Malgorzata
Galazka, Kinga
Dubiel, Krzysztof K.
Pieczykolan, Jerzy S.
Wieczorek, Maciej
机构：
来源：
DIABETES | 2019年 / 68卷
关键词：
D O I：
10.2337/db19-2333-PUB
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2333-PUB
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Discovery of TAK-875: A potent, selective, and orally bioavailable GPR40 agonist
    Negoro, Nobuyuki
    Sasaki, Shinobu
    Mikami, Satoshi
    Ito, Masahiro
    Suzuki, Masami
    Tsujihata, Yoshiyuki
    Ito, Ryo
    Harada, Ayako
    Takeuchi, Koji
    Suzuki, Nobuhiro
    Miyazaki, Junichi
    Santou, Takashi
    Kanzaki, Naoyuki
    Satou, Shinichi
    Odani, Tomoyuki
    Sakamoto, Junichi
    Funami, Miyuki
    Tanaka, Toshimasa
    Kogame, Akifumi
    Matsunaga, Shinichiro
    Yasuma, Tsuneo
    Momose, Yu
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
  • [32] Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist
    Negoro, Nobuyuki
    Sasaki, Shinobu
    Mikami, Satoshi
    Ito, Masahiro
    Suzuki, Masami
    Tsujihata, Yoshiyuki
    Ito, Ryo
    Harada, Ayako
    Takeuchi, Koji
    Suzuki, Nobuhiro
    Miyazaki, Junichi
    Santou, Takashi
    Odani, Tomoyuki
    Kanzaki, Naoyuki
    Funami, Miyuki
    Tanaka, Toshimasa
    Kogame, Akifumi
    Matsunaga, Shinichiro
    Yasuma, Tsuneo
    Momose, Yu
    ACS MEDICINAL CHEMISTRY LETTERS, 2010, 1 (06): : 290 - 294
  • [33] Discovery of AM-1638: A potent and orally bioavailable GPR40 full agonist
    Brown, Sean P.
    Dransfield, Paul J.
    Houze, Jonathan B.
    Vimolratana, Marc
    Pattaropong, Vatee
    Zhu, Liusheng
    Medina, Julio C.
    Wong, Simon
    Swaminath, Gayathri
    Lin, Dan
    Zhang, Jane
    Zhuang, Run
    Guo, Qi
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 244
  • [34] Putative association between variants in the GPR40 gene and Type 2 diabetes
    Kalis, M
    Cilio, CM
    Olde, B
    Owman, C
    Lyssenko, V
    Groop, LC
    Levéen, P
    DIABETOLOGIA, 2004, 47 : A136 - A136
  • [35] Evaluation of the hepatotoxicity of the novel GPR40 (FFAR1) agonist CPL207280 in the rat and monkey
    Bazydlo-Guzenda, Katarzyna
    Buda, Pawel
    Mach, Mateusz
    Pieczykolan, Jerzy
    Kozlowska, Izabela
    Janiszewski, Michal
    Drzazga, Ewa
    Dominowski, Jakub
    Ziolkowski, Hubert
    Wieczorek, Maciej
    Gad, Shayne Cox
    PLOS ONE, 2021, 16 (09):
  • [36] Novel GPR40 agonists for the treatment of type-2 diabetes: The effect of b-arrestin signaling
    Hamdouchi, Chafiq
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 249
  • [37] P11187, a Potent and Novel GPR40 Agonist Potentiates Glucose-Stimulated Insulin Secretion, and Improves Glucose Tolerance in Rodent Models of Type 2 Diabetes
    Anupindi, Raghuram
    Dixit, Amol
    Deshmukh, Nitin
    Gaikwad, Parikshit
    Patil, Mohan
    Khatangalekar, Vivek
    Hari, Gangadhar
    Bose, Julie
    Mehta, Chirag
    Rasal, Snehal
    Kumar, Sanjay
    Mahajan, Vishal
    Sharma, Rajiv
    Agarwal, Veena
    DIABETES, 2014, 63 : A456 - A456
  • [38] TAK-875, a Novel GPR40 Agonist, Improves Both Postprandial and Fasting Hyperglycemia in Japanese Patients with Type 2 Diabetes
    Araki, Takahiro
    Hirayama, Masashi
    Hiroi, Shinzo
    Kaku, Kohei
    DIABETES, 2011, 60 : A86 - A86
  • [39] Pharmacometric Approaches to Guide Dose Selection of the Novel GPR40 Agonist TAK-875 in Subjects With Type 2 Diabetes Mellitus
    Naik, H.
    Lu, J.
    Cao, C.
    Pfister, M.
    Vakilynejad, M.
    Leifke, E.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2013, 2 (01):
  • [40] A selective GPR40 (FFAR1) agonist provides immediate and durable glucose control in rodent models of type 2 diabetes
    Chen, Y.
    DIABETOLOGIA, 2014, 57 : S56 - S56
12345